Cambridge Investment Research Advisors
CRDL

Cambridge Investment Research Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-206,265
Closed -$280K – 3735
2025
Q2 		$280K Sell
206,265
-115,020
-36% -$134K ﹤0.01% 3040
2025
Q1 		$310K Sell
321,285
-9,220
-3% -$11.3K ﹤0.01% 2840
2024
Q4 		$424K Buy
330,505
+269,504
+442% +$454K ﹤0.01% 2563
2024
Q3 		$121K Sell
61,001
-55,130
-47% -$114K ﹤0.01% 3237
2024
Q2 		$235K Sell
116,131
-12,612
-10% -$26.8K ﹤0.01% 2904
2024
Q1 		$233K Buy
128,743
+43,542
+51% +$58.7K ﹤0.01% 2896
2023
Q4 		$72K Hold
85,201
– – ﹤0.01% 3071
2023
Q3 		$76K Buy
85,201
+8,590
+11% +$8.2K ﹤0.01% 3000
2023
Q2 		$68K Buy
76,611
+30,600
+67% +$20.2K ﹤0.01% 3053
2023
Q1 		$22K Buy
+46,011
New +$27.2K ﹤0.01% 3097

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Cambridge Investment Research Advisors's CRDL Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Cardiol Therapeutics (CRDL) in Q3 2025, closing a stake of 206,265 shares — an estimated $280K sold.

Cambridge Investment Research Advisors first reported a position in CRDL in Q1 2023 and held it in 10 quarters. The position peaked at $424K in Q4 2024. 48 funds tracked by Wall St. Rank hold CRDL as of Q3 2025.

  • Cambridge Investment Research Advisors reported no remaining Cardiol Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 206,265 Cardiol Therapeutics shares in Q3 2025, an estimated $280K.
  • Cambridge Investment Research Advisors first reported a position in Cardiol Therapeutics in Q1 2023 and held it in 10 quarters.
  • Cambridge Investment Research Advisors's Cardiol Therapeutics position peaked at $424K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.